Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 167

Sort by

Sort Order Select

Journal Articles

Impact of Presence and Amount of Clonal Plasma Cells in Autografts Affect Outcomes in High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant

Blood (2022) 140 (Supplement 1): 284–286.

https://doi.org/10.1182/blood-2022-157960

Published: 2022

Journal Articles

First in Human Study of Anti-Viral Veto Cells Enabling Successful Engraftment without Severe Gvhd in Non-Myeloablative T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)

Blood (2022) 140 (Supplement 1): 2120–2122.

https://doi.org/10.1182/blood-2022-159183

Published: 2022

Journal Articles

Transplant Outcomes for TP53 AML and MDS in a Contemporary Era

Gonca Ozcan, Uday R Popat, Partow Kebriaei, Amin M Alousi, Gheath Alatrash, Qaiser Bashir, Rohtesh S. Mehta, Jeremy L. Ramdial, Gabriela Rondon, Elizabeth J Shpall, Richard E Champlin, Betul Oran

Blood (2022) 140 (Supplement 1): 10620–10621.

https://doi.org/10.1182/blood-2022-157039

Published: 2022

Journal Articles

Phase II Trial of Venetoclax (Ven) in Combination with Azacitidine (AZA) As Maintenance Therapy for High-Risk Acute Leukemia Following Allogeneic Stem Cell Transplantation (SCT)

Betul Oran, Richard E Champlin, Peter F Thall, Jessica M McCarty, Wen Zhang, David Marin, Rohtesh S. Mehta, Amin M Alousi, Gheath Alatrash, Uday R Popat, Hagop Kantarjian, Qaiser Bashir, Elizabeth J Shpall, Marina Konopleva

Blood (2022) 140 (Supplement 1): 10561–10562.

https://doi.org/10.1182/blood-2022-159312

Published: 2022

Journal Articles

Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis

Rohtesh S. Mehta, Rima M. Saliba, Amin M Alousi, Gheath Alatrash, Qaiser Bashir, Chitra Hosing, Partow Kebriaei, Issa F. Khouri, Yago Nieto, Betul Oran, Uday R Popat, Muzaffar H Qazilbash, Jeremy L. Ramdial, Gabriela Rondon, Samer A Srour, Katy Rezvani, Richard E Champlin, Elizabeth J Shpall, Kai Cao

Blood (2022) 140 (Supplement 1): 7649–7650.

https://doi.org/10.1182/blood-2022-166381

Published: 2022

Journal Articles

Prognostic Significance of Measurable Residual Disease for Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Stem Cell Transplant in Second Complete Remission and Beyond

Oren Pasvolsky, Rima M. Saliba, Celina Ledesma, Uday R Popat, Amin M Alousi, Amanda L. Olson, Betul Oran, Chitra Hosing, Qaiser Bashir, Muzaffar H Qazilbash, Nicholas Short, Farhad Ravandi, Richard E Champlin, Elizabeth J Shpall, Partow Kebriaei

Blood (2022) 140 (Supplement 1): 7695–7696.

https://doi.org/10.1182/blood-2022-155916

Published: 2022

Journal Articles

HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT

Rohtesh S. Mehta, Rima M. Saliba, Amin M. Alousi, Gheath Alatrash, Qaiser Bashir, Chitra Hosing, Partow Kebriaei, Issa F. Khouri, Yago Nieto, Betul Oran, Uday R. Popat, Muzaffar H. Qazilbash, Jeremy L. Ramdial, Gabriela Rondon, Samer A. Srour, Katy Rezvani, Richard E. Champlin, Elizabeth J. Shpall, Kai Cao

Blood (2022) 140 (Supplement 1): 4880–4881.

https://doi.org/10.1182/blood-2022-158689

Published: 2022

Journal Articles

Mother Vs Father Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis

Rohtesh S. Mehta, Rima M. Saliba, Amin M Alousi, Gheath Alatrash, Qaiser Bashir, Partow Kebriaei, Issa F. Khouri, Yago Nieto, Betul Oran, Uday R Popat, Muzaffar H Qazilbash, Jeremy L. Ramdial, Gabriela Rondon, Samer A Srour, Katy Rezvani, Richard E Champlin, Elizabeth J Shpall, Kai Cao

Blood (2022) 140 (Supplement 1): 10530–10531.

https://doi.org/10.1182/blood-2022-166472

Published: 2022

Journal Articles

Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience

Oren Pasvolsky, Denái R Milton, Adeel Masood, Sophiya S Shehzad, Mark R Tanner, Qaiser Bashir, Samer A Srour, Neeraj Saini, Jeremy L. Ramdial, Yago Nieto, Hans C. Lee, Krina Patel, Partow Kebriaei, Sheeba K Thomas, Donna M. Weber, Robert Z. Orlowski, Elizabeth J Shpall, Richard E Champlin, Muzaffar H Qazilbash

Blood (2022) 140 (Supplement 1): 10589–10591.

https://doi.org/10.1182/blood-2022-162465

Published: 2022

Journal Articles

Initial Results of a Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in Newly Diagnosed and Previously Treated AL Amyloidosis

Hans C. Lee, Gregory P. Kaufman, Lei Feng, Astrid Murga, Ralph J. Johnson, Donna M. Weber, Sheeba K Thomas, Qaiser Bashir, Muzaffar H Qazilbash, Swaminathan P. Iyer, Krina Patel, Melody R. Becnel, Elisabet E. Manasanch, Robert Z. Orlowski

Blood (2022) 140 (Supplement 1): 4428–4430.

https://doi.org/10.1182/blood-2022-167555

Published: 2022

Journal Articles

A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma

Blood (2022) 139 (9): 1289–1301.

https://doi.org/10.1182/blood.2020008493

Published: 2022

Includes: Supplemental data

Journal Articles

Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial

Blood (2021) 138 (Supplement 1): 2879.

https://doi.org/10.1182/blood-2021-146253

Published: 2021

Journal Articles

Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy

Blessie Elizabeth Nelson, Jeremy L. Ramdial, Qaiser Bashir, Neeraj Saini, Chitra Hosing, Uday R. Popat, Ruby Delgado, Hans C. Lee, Gregory P. Kaufman, Robert Z. Orlowski, Richard E. Champlin, Muzaffar H. Qazilbash, Samer A. Srour

Blood (2021) 138 (Supplement 1): 482.

https://doi.org/10.1182/blood-2021-154277

Published: 2021

Journal Articles

Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial

Blood (2021) 138 (Supplement 1): 556.

https://doi.org/10.1182/blood-2021-152450

Published: 2021

Journal Articles

Incidence and Outcomes of Toxoplasma Reactivation in Patients with Hematologic Diseases after Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2021) 138 (Supplement 1): 1779.

https://doi.org/10.1182/blood-2021-151474

Published: 2021

Journal Articles

Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial

Blood (2021) 138 (Supplement 1): 1802.

https://doi.org/10.1182/blood-2021-146655

Published: 2021

Journal Articles

Post-Transplant Cyclophosphamide Versus Tacrolimus and Methotrexate to Prevent Graft-Versus-Host Disease in Recipients of Matched Donor Transplantation: Comparison of Sequential Cohorts in a Prospective Trial

Blood (2021) 138 (Supplement 1): 1803.

https://doi.org/10.1182/blood-2021-146245

Published: 2021

Journal Articles

Disease Characteristics of Multiple Myeloma Involving BRAF Mutations

Shehab Fareed Mohamed, Maliha Khan, Andres Quesada, Junsheng Ma, Pei Lin, C. Cameron Yin, Koji Sasaki, Gautam Borthakur, Naveen Pemmaraju, Qaiser Bashir, Muzaffar H. Qazilbash, Gregory P. Kaufman, Melody R. Becnel

Blood (2021) 138 (Supplement 1): 4755.

https://doi.org/10.1182/blood-2021-147400

Published: 2021

Journal Articles

A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule and Dose of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma

Blood (2021) 138 (Supplement 1): 3941.

https://doi.org/10.1182/blood-2021-149807

Published: 2021

Journal Articles

Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Post-Transplant Myeloma Patients

Krina K. Patel, Jatin J. Shah, Lei Feng, Hans C. Lee, Elisabet E. Manasanch, Jasper B. Olsem, Ashley N. Morphey, Xiao Jiao Huo, Qaiser Bashir, Sheeba K Thomas, Muzaffar H. Qazilbash, Donna M. Weber, Robert Z. Orlowski

Blood (2021) 138 (Supplement 1): 4774.

https://doi.org/10.1182/blood-2021-151950

Published: 2021

NARROW

Impact of Presence and Amount of Clonal Plasma Cells in Autografts Affect Outcomes in High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant

First in Human Study of Anti-Viral Veto Cells Enabling Successful Engraftment without Severe Gvhd in Non-Myeloablative T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)

Transplant Outcomes for TP53 AML and MDS in a Contemporary Era

Phase II Trial of Venetoclax (Ven) in Combination with Azacitidine (AZA) As Maintenance Therapy for High-Risk Acute Leukemia Following Allogeneic Stem Cell Transplantation (SCT)

Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis

Prognostic Significance of Measurable Residual Disease for Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Stem Cell Transplant in Second Complete Remission and Beyond

HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT

Mother Vs Father Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis

Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience

Initial Results of a Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in Newly Diagnosed and Previously Treated AL Amyloidosis

A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma

Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial

Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy

Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial

Incidence and Outcomes of Toxoplasma Reactivation in Patients with Hematologic Diseases after Allogeneic Hematopoietic Stem Cell Transplantation

Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial

Post-Transplant Cyclophosphamide Versus Tacrolimus and Methotrexate to Prevent Graft-Versus-Host Disease in Recipients of Matched Donor Transplantation: Comparison of Sequential Cohorts in a Prospective Trial

Disease Characteristics of Multiple Myeloma Involving BRAF Mutations

A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule and Dose of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma

Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Post-Transplant Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only